Expert Illustrations and Commentaries: Translating Advances in XLH and TIO Into Practical Strategies for Management

Release Date: January 20, 2021
Expiration Date: January 20, 2022

Activity Overview

As chronic diseases, X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) have a debilitating impact on the quality of life of affected patients. In XLH, significant complications result from unresolved symptoms in childhood, as well as from disease progression. In TIO, difficulties locating or resecting the causative tumor can result in lifelong morbidity. Unfortunately, knowledge of these conditions is also limited, and many patients experience delayed diagnoses and ineffective treatment.

This activity provides clinicians with a deeper understanding of XLH and TIO in terms of the pathophysiology and clinical presentation so they can better manage patients. In this activity, the faculty describe available novel therapies and their unique mechanisms in order to better select treatments for patients. They also explain the mechanism of action of novel therapies for XLH and TIO. In addition, a white board animation helps to illustrate this for participants.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the pathophysiological basis for the development of symptoms in patients with XLH or TIO
• Identify clinical presentations of XLH and TIO that warrant further investigation and diagnostic testing
• Discuss the mechanisms of action for novel and emerging therapies in the management of patients with XLH or TIO
• Apply traditional and emerging therapeutic approaches toward the development of management plans for patients with XLH or TIO

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Thomas O. Carpenter, MD
Professor of Pediatrics (Endocrinology),
Professor of Orthopedics and Rehabilitation
Yale University School of Medicine
New Haven, CT

Disclosures: Grant Research Support: Ultragenyx; Consultant: Ultragenyx, Inozyme Pharma, Regeneron Pharmaceuticals, Kyowa Hakko Kirin Pharma.

Peter Tebben, MD
Mayo Clinic
Departments of Internal Medicine and Pediatrics
Division of Endocrinology
Rochester, MN

Disclosures: Grant Research Support: Ultragenyx; Other: Ultragenyx: CME.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.